Advertisement

Urolithiasis pp 511-516 | Cite as

Physicochemical Action and Extrarenal Manifestations of Alkali Therapy

  • C. Y. C. Pak

Abstract

Since the last international conference on urolithiasis in 1984, citrate has received increasing recognition as an important pathogenetic factor in stone formation and as a therapeutic agent in the prevention of recurrent nephrolithiasis. Since other speakers will have covered pathophysiology of hypocitraturia and clinical response to citrate therapy, I shall consider the following topics.

Keywords

Calcium Oxalate Calcium Excretion Intestinal Calcium Absorption Potassium Citrate Distal Renal Tubular Acidosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    JJ Meyer and LH Smith, Invest. Urol. 13: 36 (1975).PubMedGoogle Scholar
  2. 2.
    CYC Pak, MJ Nicar, and C Northcutt, in: “Contributions to Nephrology”, GM Berlyne, S Giovanetti, and S Thomas, eds., Karger, Basel, 33: 136 (1982).Google Scholar
  3. 3.
    MJ Nicar, K Hill, and CYC Pak, J. Bone Min. Res. 2: 215 (1987).CrossRefGoogle Scholar
  4. 4.
    DJ Kok, SE Papapoulos, and OLM Bijvoet, The Lancet May 10: 1056 (1986).CrossRefGoogle Scholar
  5. 5.
    CYC Pak and R Peterson, Arch. Int. Med. 146: 863 (1986).CrossRefGoogle Scholar
  6. 6.
    CYC Pak, Min. Elec. Metab. 13: 257 (1987).Google Scholar
  7. 7.
    CYC Pak, J. Urol. 140: 461 (1988).PubMedGoogle Scholar
  8. 8.
    CYC Pak, K Sakhaee, and C Fuller, Kidney Int. 30: 422 (1986).PubMedCrossRefGoogle Scholar
  9. 9.
    JG Gregory, KY Park, R Wilt, and A Geigl, in: “Urolithiasis: Clinical and Basic Research”, LH Smith, WG Robertson, and B Finlayson, eds., Plenum Press, New York (1981).Google Scholar
  10. 10.
    M Butz and HJ Dulce, in: “Urolithiasis: Clinical and Basic Research”, LH Smith, WG Robertson, and B Finlayson, eds., Plenum Press, New York (1981).Google Scholar
  11. 11.
    PO Schwille, G Rumenapf, H Schwarzlander, P Kuch, and H Berens, in: “Inhibitors of Crystallization in Renal Lithiasis and Their Clinical Application”, A Martelli, P Buli, and B Marchesini, eds., Acta Medica, Rome (1987).Google Scholar
  12. 12.
    J Lutz, Am. J. Clin. Nutr. 39: 281 (1984).PubMedGoogle Scholar
  13. 13.
    MJ Nicar, MC Hsu, and C Fetner, Clin. Therapeutics 8: 219 (1986).Google Scholar
  14. 14.
    K Sakhaee, M Nicar, K Hill, and CYC Pak, Kidney Int. 24: 348 (1983).PubMedCrossRefGoogle Scholar
  15. 15.
    GM Preminger, K Sakhaee, and CYC Pak, J. Urol. 139: 240 (1988).PubMedGoogle Scholar
  16. 16.
    CYC Pak and C Fuller, Ann. Intern. Med. 104: 33 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    GM Preminger, K Sakhaee, and CYC Pak, Metabolism 36: 176 (1987).PubMedCrossRefGoogle Scholar
  18. 18.
    CYC Pak, JA Harvey, and MC Hsu, J. Clin. Endocrinol. Metab. 65: 801 (1987).PubMedCrossRefGoogle Scholar
  19. 19.
    RR Recker, NEJM 313: 70 (1985).PubMedCrossRefGoogle Scholar
  20. 20.
    J Lemann, JA Pleuss, and RW Gray, in: “Abstracts”, The American Soc. of Nephrology 19th Annual Meeting, Dec. 7–10, 1986.Google Scholar
  21. 21.
    DA Bushinsky, Am. J. Physiol. 254: F306 (1988).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • C. Y. C. Pak
    • 1
  1. 1.Center for Mineral Metabolism and Clinical Research Department of Internal MedicineUniversity of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations